<p>(A) VEGFR2 - beta<sub>3</sub> integrin - neuropilin1 (NRP1) co-immunoprecipitate <i>in vivo,</i> shown by reciprocal VEGFR2 and beta<sub>3</sub> integrin IP. Negative control is rabbit serum (RS). Immunoprecipitates were blotted with VEGFR2, beta<sub>3</sub> integrin, Y<sup>1175</sup>-VEGFR2, anti S<sup>785</sup>- beta<sub>3</sub> integrin and neuropilin-1 antibodies. (B) VEGFR2 - beta<sub>3</sub> integrin – NRP1 co-immunoprecipitate in cultured podocytes. IPs were performed as described in (A) using VEGF<sup>KD</sup> podocyte lysates. (C) Dual-immunostaining shows decreased active alpha<sub>v</sub>beta<sub>3</sub> integrin (WOW-1) and total beta<sub>3</sub> integrin in glomeruli from VEGF knockdown mice. (D) Immunocytochemistry shows de...
<div><p>Integrins mediate cell adhesion, migration, and survival by connecting intracellular machine...
<p>Tissues that express low levels of Neuropilin-1 are insensitive to all Neuropilin-targeting treat...
The blockade of tumour vascularisation and angiogenesis continues to be a focus for drug development...
Both vascular endothelial growth factor receptors (VEGFR) and integrins are major regulators of VEGF...
<p>(A) Representative immunoblots show decreased alpha<sub>V</sub>beta<sub>3</sub> integrin in VEGF ...
<div><p>Podocyte or endothelial cell VEGF-A knockout causes thrombotic microangiopathy in adult mice...
Podocyte or endothelial cell VEGF-A knockout causes thrombotic microangiopathy in adult mice. To stu...
<div><p>(A–C) The time course of VEGF–VEGFR2 complex formation on the endothelial cells following ea...
Lymphatic vascular development is regulated by vascular endothelial growth factor receptor-3 (VEGFR-...
<p>(A) Cell Tracker (green) and rhodamine phalloidin (red) labeling shows images of spindle-like und...
This review advances the hypothesis that the ability of integrins to engage their extracellular matr...
<p><i>A,</i> Mouse eye cups of each group were treated with EGFL7 or control siRNA after embedding t...
<p>(<b>A</b>) Expression of VEGF-R2 and R3 mRNA examined with semi quantitative RT-PCR, and (<b>B</b...
Anti-angiogenic treatments against αvβ3-integrin fail to block tumour growth in the long term, which...
<div><p>(A–C) Formation of VEGF–VEGFR2 complexes over time following anti-Neuropilin treatment, for ...
<div><p>Integrins mediate cell adhesion, migration, and survival by connecting intracellular machine...
<p>Tissues that express low levels of Neuropilin-1 are insensitive to all Neuropilin-targeting treat...
The blockade of tumour vascularisation and angiogenesis continues to be a focus for drug development...
Both vascular endothelial growth factor receptors (VEGFR) and integrins are major regulators of VEGF...
<p>(A) Representative immunoblots show decreased alpha<sub>V</sub>beta<sub>3</sub> integrin in VEGF ...
<div><p>Podocyte or endothelial cell VEGF-A knockout causes thrombotic microangiopathy in adult mice...
Podocyte or endothelial cell VEGF-A knockout causes thrombotic microangiopathy in adult mice. To stu...
<div><p>(A–C) The time course of VEGF–VEGFR2 complex formation on the endothelial cells following ea...
Lymphatic vascular development is regulated by vascular endothelial growth factor receptor-3 (VEGFR-...
<p>(A) Cell Tracker (green) and rhodamine phalloidin (red) labeling shows images of spindle-like und...
This review advances the hypothesis that the ability of integrins to engage their extracellular matr...
<p><i>A,</i> Mouse eye cups of each group were treated with EGFL7 or control siRNA after embedding t...
<p>(<b>A</b>) Expression of VEGF-R2 and R3 mRNA examined with semi quantitative RT-PCR, and (<b>B</b...
Anti-angiogenic treatments against αvβ3-integrin fail to block tumour growth in the long term, which...
<div><p>(A–C) Formation of VEGF–VEGFR2 complexes over time following anti-Neuropilin treatment, for ...
<div><p>Integrins mediate cell adhesion, migration, and survival by connecting intracellular machine...
<p>Tissues that express low levels of Neuropilin-1 are insensitive to all Neuropilin-targeting treat...
The blockade of tumour vascularisation and angiogenesis continues to be a focus for drug development...